Where does the Paradigm Biopharmaceuticals share price go from here?

Paradigm Biopharmaceuticals Ltd (ASX: PAR): buy, hold, sell?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At the start of April, the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price reached $2.02. Much of Paradigm's share price increase was in anticipation of secondary end point results for its phase 2b osteoarthritis trials.

The recent trial report showed extremely positive results.

Most importantly, it was found that Paradigm's repurposed drug showed a stark difference between itself and the placebo. The results were verified using an MRI scan which measured the lesion caused by bone marrow edema.

At day 53 of treatment, Paradigm's repurposed drug showed a reduced bone marrow lesion volume of 34% vs the placebos 3.6%. Furthermore, the bone marrow lesion area increased in the placebo group by 11.9% compared to a 25.3% decrease in the treatment group.

The objective results obtained were also statistically significant with a p-value of 0.03, meaning that it's highly likely that Paradigm's repurposed drug is causing the improvement of bone marrow lesions.

Why did the Paradigm share price not respond accordingly?

Despite fantastic secondary endpoint results from Paradigm, the share price did not react positively.

The cause can be attributed to Paradigm's capital raise at a significant discount which was announced alongside the secondary endpoint results.

Although Paradigm's share price could have responded better, Paradigm received strong attention for its $77.9 million capital raise which should be filled promptly.

Paradigm expects a cash level of $82 million post raise which will allow it to take its repurposed drug through phase 3 trials.

Additionally, a strong cash position by Paradigm will ensure a better offer from potential future negotiators.

At this stage, Paradigm is aware that it has a potential blockbuster drug on its hands and therefore wouldn't give it up without a significant premium.

Where does Paradigm go from here?

Paradigm has multiple share price catalysts coming up. These include the phase 2/3 clinical trials for MPS and the approval for selling its repurposed drug in Australia.

With the results obtained from its phase 2b trials, Paradigm has significantly de-risked its repurposed drug for phase 3.

Foolish takeaway 

Paradigm Biopharmaceuticals is currently well positioned to take its repurposed drug into phase 3 clinical trials. If Paradigm succeeds throughout phase 3, the share price could take off for many years to come.

For other growth companies, be sure to check out…

Motley Fool contributor Elton Wang owns shares of PARADIGM BIO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Happy miner giving ok sign in front of a mine.
Opinions

Which ASX 200 stock offers 'material upside' amid continuing uncertainty over US tariffs?

Blackwattle Investment has identified one ASX 200 large-cap stock that is thriving on the uncertainty.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Bapcor, Boss Energy, Macquarie, and Novonix shares are falling today

These shares are having a tough session on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Financial Shares

2 rising ASX financial shares with 'meaningful upside' still left: fundie

Financials outperformed every other sector in FY25, but there are still buying opportunities left, say these experts.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

Stock market crash concept of young man screaming at laptop on the sofa.
Share Fallers

Guess which ASX 200 stock just crashed 31% on slumping sales

The $1.3 billion ASX 200 stock is getting hammered today.

Read more »

A woman walks along the street holding an oversized box wrapped as a gift.
Broker Notes

Fundie reveals why these 3 ASX 200 large-cap shares ripped 35% to 96% in FY25

Blackwattle Investment Partners discusses the performance and outlook for 3 ASX 200 shares in its Large Cap Quality Fund.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Broker Notes

This fund manager just delivered a stellar year and he's bullish on these 5 stocks

With standout returns in both Australian and global equities, Andrew Mitchell shares five high-conviction stocks primed for long-term growth.

Read more »

A woman ponders over what to buy as she looks at the shelves of a supermarket.
Broker Notes

Does Macquarie prefer Woolworths or Coles shares today?

Which supermarket giant was recently named the favourite?

Read more »